iScience (Sep 2024)

FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation

  • Guixia Zhang,
  • Xintian Chen,
  • Caiyuan Yu,
  • Lijiao Cui,
  • Ningning Chen,
  • Guanrong Yi,
  • Shan Wang,
  • Haiyun Wei,
  • Youxin Liang,
  • Shicai Ye,
  • Yu Zhou

Journal volume & issue
Vol. 27, no. 9
p. 110730

Abstract

Read online

Summary: Folliculin interacting protein 1 (FNIP1) primarily participates in regulating cellular energy metabolism and is associated with Birt-Hogg-Dubé (BHD) syndrome. Although FNIP1 has been demonstrated to function as both a tumor suppressor and promoter, its role in colorectal cancer (CRC) remains unclear. Our study demonstrated a significant downregulation of FNIP1 in CRC, correlating with shorter overall and disease-specific survival. FNIP1 may potentially serve as an independent prognostic factor in CRC. Moreover, FNIP1 inhibited CRC progression in vitro and in vivo. Mechanistically, FNIP1 bound to phosphorylated signal transducer and activator of transcription-3 (p-STAT3) and downregulated its expression. FNIP1 deletion increased STAT3 phosphorylation and nuclear localization, thereby promoting CRC progression. The use of p-STAT3-specific chemical inhibitors successfully mitigated excessive tumorigenesis resulting from FNIP1 absence. Thus, our results suggest that FNIP1 hinders CRC progression by suppressing STAT3 phosphorylation and nuclear translocation. FNIP1 may be a candidate prognostic indicator and a therapeutic target for intervention in CRC.

Keywords